APT Pharmaceuticals Garners $32,000,000 Series B Round

  • Feed Type
  • Date
    9/30/2008
  • Company Name
    APT Pharmaceuticals
  • Mailing Address
    700 Airport Blvd. Burlingame, CA 94010
  • Company Description
    APT Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing products to treat asthma, chronic pulmonary obstructive disease, rhinitis and rhinovirus.
  • Website
    http://www.aptbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $32,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to complete APT’s pivotal Phase III program evaluating the safety and efficacy of cyclosporine inhalation solution following lung transplantation. The Series B financing will also fund further development of the company’s pipeline programs in serious lung diseases.
  • M&A Terms
  • Venture Investor
    Three Arch Partners
  • Venture Investor
    InterWest Partners
  • Venture Investor
    Pinnacle Ventures
  • Venture Investor
    Charter Life Sciences Fund
  • Venture Investor
    Great Point Partners
  • Venture Investor
    Versant Ventures
  • Venture Investor
    Vivo Ventures

Trending on Xconomy